Skip to main content
Premium Trial:

Request an Annual Quote

FDA's Personalized Medicine Leader Leaving for Liquid Biopsy Startup Grail

NEW YORK (GenomeWeb) – Elizabeth Mansfield, who currently heads the US Food and Drug Administration's personalized medicine group within the device division, is leaving the agency this month to join Grail, which aims to develop a blood test for early cancer detection.

According to an FDA spokesperson, Mansfield, currently the deputy director for personalized medicine at the agency's Office of In Vitro Diagnostics and Radiological Health, will be leaving the post on February 17. Mansfield joined the agency in 2006 and led efforts to advance regulations for precision medicine and next-generation sequencing.

"Dr. Mansfield's leadership at FDA helped turn personalized medicine from aspiration to reality," Personalized Medicine Coalition President Edward Abrahams said in a statement. "As director and coordinator of the agency's manifold personalized medicine programs, she pushed to replace antiquated regulatory policies with smart proactive ones that encouraged innovation while also protecting patients." As a result of her efforts, he highlighted that more than 20 percent of all new molecular entities the FDA has approved for the last three years are personalized medicines.

At Grail, Mansfield will be head of regulatory strategy. The liquid biopsy startup secured over $100 million in Series A financing from Illumina, ARCH Venture Partners, and participating investors Bezos Expeditions, Bill Gates, Sutter Hill Ventures, and GV. In January, the company announced its goal to raise $1 billion in a series B financing round.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.